BridgeBio Pharma Operating Income 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BridgeBio Pharma operating income from 2018 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

BridgeBio Pharma Operating Income 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BridgeBio Pharma operating income from 2018 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.4B
Dr Reddy's Laboratories (RDY)	$11.9B
Bausch Health Cos (BHC)	$2.9B
Amphastar Pharmaceuticals (AMPH)	$2.2B
Supernus Pharmaceuticals (SUPN)	$2B
Taysha Gene Therapies (TSHA)	$506M
Personalis (PSNL)	$245M
Assembly Biosciences (ASMB)	$96M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$6M
Teligent (TLGT)	$0M